Behçet's disease (BD) is more common in eastern than western countries. Physicians have frequently encountered problems in its treatment, especially eye involvement. Recurrent oral and genital aphthous ulcerations are the hallmarks of Behçet’s disease but other organs can be involved and ocular disease is one of the most disabling manifestations. Up to now, there are some problems in treatment of the retinal vasculitis due to Behçet’s disease. We reported one patient, with visual loss due to retinal vasculitis that was resistant to prednisolone and azathioprine. Our patient was treated successfully with rituximab and his remission was sustained for 24 months of follow-up. Rituximab is a chimeric monoclonal antibody that acts against the specific B cell antigen, CD20. The recent success of rituximab in autoimmune diseases, which is considered to be T cell-mediated, indicates that B cells must have a much broader role in the pathogenesis of autoimmune diseases than generally appreciated.
Rituximab Behçet's disease Retinal vasculitis
This is a preview of subscription content, log in to check access.
Kansu T, Kadayifcilar S. Visual aspects of Behçet’s disease. Curr Treat Options Neurol. 2007;8:81–8.CrossRefGoogle Scholar
Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol. 1980;125:1678–85.PubMedGoogle Scholar
Davachi F. New and innovative therapies for Behçet’s disease. APLAR J Rheum. 2004;7:141–5.CrossRefGoogle Scholar
Kneitz C, Wilhelm M, Tony H. Effective B cell depletion with rituximab in treatment of autoimmune diseases. J Immunobiol. 2002;206:519–27.CrossRefGoogle Scholar
Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22:7359–68.PubMedCrossRefGoogle Scholar
Edwards JCW, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, et al. Efficacy of B-cell–targeted therapy with rituximab in patients with rheumatoid arthritis. New Engl J Med. 2004; 350:2572–81.PubMedCrossRefGoogle Scholar
Cheung CM, Murray PI, Savage CO. Successful treatment of Wegener’s granulomatosis associated scleritis with rituximab. Br J Ophthalmol. 2005;89:1542.PubMedCrossRefGoogle Scholar
Ahmadi-Simab K, Lamprecht P, Nolle B, Ai M. Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab. Ann Rheum Dis. 2005;64:1087–8.PubMedCrossRefGoogle Scholar
Kaushik VV, Reddy HV, BucknalR C. Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome. Ann Rheum Dis. 2006;65:1116–7.PubMedCrossRefGoogle Scholar
Eksioglu-Demiralp E, Kibaroglu A, Direskeneli H, et al. Phenotypic characteristics of B cells in Behçet's disease: increased activity in B cell subsets. J Rheumatol. 1999;26:826–32.PubMedGoogle Scholar
Looney RJ, Anolik JH, Campbell D, Felgar RE, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004;50:2580–9.PubMedCrossRefGoogle Scholar